Fulcrum Therapeutics to Present at the Annual Society for Neuroscience Meeting

Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, will present at the Society for Neuroscience Annual Meeting held from November 11-15 in Washington, D.C.

Fulcrum Therapeutics to Present at the 18th Annual Fragile X and Related Neurodevelopmental Disorders Workshop

Cambridge, Mass., Oct. 11, 2017 – Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, will present at the 18th International Fragile X and Related Neurodevelopmental Disorders Workshop, held in Quebec, Canada from October 12-16, 2017. Read More. 

Fulcrum Therapeutics to Present at the 10th Annual BioPharm America International Partnering Conference

Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies that unlock gene regulation to treat serious genetic diseases, will present at the 10th Annual BioPharm America International Partnering Conference in Boston, Mass.

Robert Gould, Ph.D., Fulcrum’s President and Chief Executive Officer, will give a presentation in the Rare and Orphan Disease category titled “Restoring Balance in Gene Regulation” at the Sheraton Boston Hotel on September 27th at 10:45am. Read More.

Fulcrum Therapeutics to Present at BioCentury’s 24th Annual NewsMakers in the Biotech Industry Conference

Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies that unlock gene regulation to treat serious genetic diseases, will present at BioCentury’s 24th Annual NewsMakers in the Biotech Industry Conference, to be held September 8, 2017 in New York City.

Robert Gould, Ph.D., Fulcrum’s President and Chief Executive Officer, and Amit Hasija, Chief Business Officer, will give a presentation titled “Restoring Balance in Gene Regulation” at 11:30 a.m. at the Millennium Broadway Hotel & Conference Center.

 

Fulcrum Therapeutics Named Finalist for the 2017 Xconomy Awards in the Patient Partnership Category

Cambridge, Mass., August 9, 2017 – Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, today announced that it has been named a finalist for the 2017 Xconomy Awards in the Patient Partnership category. Read More.

Fulcrum Therapeutics Announces Additional Series A Financing from GV

Cambridge, Mass., May 10th, 2017 – Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, today announced that it has secured additional Series A funding from GV (formerly Google Ventures) to support the continued advancement of Fulcrum’s lead programs in Fragile X syndrome (FXS) and Facioscapulohumeralmuscular dystrophy (FSHD).

Fulcrum Therapeutics Expands Leadership Team with Appointment of Owen Wallace, Ph.D., as Chief Scientific Officer and Amit Hasija as Chief Business Officer

Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, today announced the appointments of Owen Wallace, Ph.D., as Chief Scientific Officer and Amit Hasija as Chief Business Officer.

Fulcrum Therapeutics Strengthens its Board of Directors with the Addition of Alan Ezekowitz, MBChB, D.Phil., and James J. Collins, Ph.D.

Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, today announced the appointment of Alan Ezekowitz, MBChB, D.Phil., and James J. Collins, Ph.D., to its Board of Directors. Read More.